Qfix™ Access 360™ Prone Breast Treatment Solution Treating women with breast cancer in the prone position during radiation therapy may substantially cut the radiation dose that reaches their heart and lungs. Avondale, PA – September 28, 2011 – Qfix (www.qfix.com) announces the release of the kVue™ Access 360™ Prone Breast treatment solution to improve treatment options for women with breast cancer. Studies suggest that using this prone breast technique during radiotherapy minimizes the risk of damage to the heart, lungs and surrounding structures. This lowers the risk of complications, such as future heart disease, lung damage and poor cosmesis. The kVue™ Access 360™ features a specially designed opening which allows the ipsilateral breast and chest wall to hang down away from the thorax, while the contralateral breast remains cushioned on the foam pad on top of the device. The unique design provides near 360 degree access to the breast and supraclavicular nodes for improved imaging and treatment. A CT docking solution allows seamless transition from simulation to treatment. Qfix and Varian Medical systems have joined efforts to design the Access 360™ for prone breast care. Varian Medical Systems Pivotal™ Treatment Solutions combines prone techniques with the innovative kVue™ Access 360™ device. The design enables treatment of both right and left breast, including whole breast, partial breast and accelerated partial breast treatments (APBI). “The kVue™ Access 360™ is the latest offering in a line of unique and innovative positioning devices that we at Qfix have developed over the past decade,” commented Dan Coppens, CEO & Technical Director of Qfix. “We are thrilled to have Varian as our partner in developing such innovative treatment solutions. With the launch of the kVue™ Access 360™, we have an opportunity to make a significant difference in breast cancer treatment.” About kVue™ IGRT ------------ For additional information contact: QfixTM Announces SpiroDynr’X (SDX) Radiotherapy Breathing Control System Avondale, PA, July 20, 2010 – QfixTM has announced an exclusive distribution agreement with Dyn’R for the company’s SDX™ Radiation Therapy Breathing Control System, now available to healthcare providers throughout the United States. The SDX enables reproducible positioning of the tumor from medical imaging through the final session of the treatment, thus reducing the irradiation of healthy tissues and contiguous organs. During the initial preparation phase, the patient learns to use the spirometer, and the clinical team determines the optimal breath hold level according to the patient’s respiratory capacity. The patient is then asked to voluntarily reproduce the breath holds at the same pulmonary volume level during each subsequent medical imaging and radiation therapy session. The SDX’s ergonomics are expressly designed for passage through existing CT scanners. Coupled with intuitive software, the SDX is easy to use by the Radiation Therapy team. The voluntary breath hold method makes it possible to obtain high quality images in which the effects of respiratory movement are minimized, thus contributing to optimized dosimetry planning. During each Radiation Therapy session, the patient produces several breath holds, lasting from a few to approximately 20 seconds. The use of video goggles provides bio-feedback to the patient indicating when and for how long to produce the breath hold. 95% of patients are able to master this method, regardless of the respiratory pathology from which they suffer. The patient’s active involvement is an important motivating factor contributing to successful completion of the treatment cycle. “We are excited about driving SDX™ availability throughout North America. The SDX breath hold system provides a unique and patented method for ensuring accurate tumor motion control and positioning. It represents a valuable complement to our extensive portfolio of patient positioning products which also includes our Stradivarius™ system for SBRT”, says Dan Coppens, Chief Executive Officer of Qfix. “Our partnership with Dyn’R provides additional proof of our determination to bring premium solutions to the radiation oncology community. About Qfix About Dyn’R Forward-Looking Statements ------------ For additional information contact: Qfix™ AnnouncesDistribution Agreement with MEDRAD PRO-TEKT™ Endorectal Balloon Enables Repeatable Positioning with New Design to Minimize Discomfort During Radiation Therapy Avondale, Pa., August 19, 2010 – Qfix™ has announced an exclusive distribution agreement with MEDRAD for the company’s PRO-TEKT™ endorectal balloon device. The PRO-TEKT device immobilizes structures that surround the rectum, such as the prostate, for radiation therapy treatment. The device is now available to healthcare providers throughout the United States, Australia and Europe. The disposable single-use device immobilizes the rectal wall and adjacent structures of the ”The PRO-TEKT device can help the radiation oncologist consider reducing field margins which may decrease side effects to organs that are adjacent to the tumor,” says Anthony Cinalli, Executive Director of Marketing, MEDRAD Radiology. We are enthusiastic about accelerating PRO-TEKT product availability worldwide through Qfix distribution.” “The PRO-TEKT device strengthens our leadership position in delivering a comprehensive suite MEDRAD has developed and manufactured products designed to support prostate cancer management for more than a decade. In addition to manufacturing the PRO-TEKT endorectal balloon, MEDRAD manufactures and sells the Prostate eCoil™ MRI endorectal coil, a device that enables improved insight for early prostate cancer detection. About MEDRAD, Inc. Forward-Looking Statements ------------ For additional information contact: |
Qfix Announces kVue Access 360 Prone Breastboard Couchtop Insert Qfix Announces Distribution Agreement with DynR
|
Phone 1-610-268-0585 Fax 610-268-0588 E-mail: Sales@Qfix.com
Website Design by Cerezastudios.com